Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.57% | 14.60% | 18.26% | -800.76% | 119.59% |
| Total Depreciation and Amortization | -3.06% | -8.41% | -49.77% | 28.31% | -66.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -81.83% | -320.31% | -150.23% | 103.66% | -373.37% |
| Change in Net Operating Assets | -127.49% | -183.86% | -2,352.74% | 98.73% | -1,182.13% |
| Cash from Operations | -33.22% | -6.61% | 6.76% | -6.21% | -5.13% |
| Capital Expenditure | -527.19% | -208.11% | -1,750.00% | 99.56% | 31.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.15% | -290.85% | 13.64% | -27.99% | 29.69% |
| Cash from Investing | 100.39% | -291.22% | 13.56% | -27.44% | 30.57% |
| Total Debt Issued | -73.17% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 72.27% | 12.80% | 2,914.29% | -91.57% | 538.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -72.70% | 67,045.50% | 2,914.29% | -91.57% | 538.46% |
| Foreign Exchange rate Adjustments | -100.00% | -83.33% | 700.00% | -103.03% | 217.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,224.95% | -147.78% | 176.41% | -137.88% | 552.05% |